Fulgent Genetics, Inc. (FLGT)

Market Cap	462.96M -14.8%
Revenue (ttm)	322.67M +13.8%
Net Income	-60.51M
EPS	-1.97
Shares Out	28.84M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,885
Open	16.24
Previous Close	16.26
Day's Range	15.91 - 16.40
52-Week Range	13.46 - 31.04
Beta	0.89
Analysts	Buy
Price Target	28.33 (+76.51%)
Earnings Date	May 1, 2026

About FLGT

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive he...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Sep 29, 2016
• Employees: 1,315
• Stock Exchange: NASDAQ
• Ticker Symbol: FLGT
• Website: https://www.fulgentgenetics.com

Financial Performance

In 2025, Fulgent Genetics's revenue was $322.67 million, an increase of 13.83% compared to the previous year's $283.47 million. Losses were -$60.51 million, 41.7% more than in 2024.

Analyst Summary

According to 3 analysts, the average rating for FLGT stock is "Buy." The 12-month stock price target is $28.33, which is an increase of 76.51% from the latest price.

Price Target

$28.33

(76.51% upside)

Analyst Consensus: Buy